Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Even after failing another MEK inhibitor, patients with neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas can still benefit from mirdametinib (Gomekli). Data from the phase 2b ReNeu trial show that longer treatment deepens tumor responses over time, with response rates climbing and side effects tapering off. Experts say switching MEK inhibitors when one stops working is a reasonable and promising strategy.
Mirdametinib (Gomekli) is showing real promise for patients with neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas — even those who've already been through another MEK inhibitor. A post hoc analysis of the phase 2b ReNeu trial found that among 10 patients with prior MEK inhibitor exposure (including selumetinib, trametinib, and cobimetinib), all achieved either stable disease or a partial response on mirdametinib. Two children had partial responses with tumor volume reductions of up to 56.9%, and two early access program patients reported meaningful symptom improvements after switching.
Longer-term ReNeu data presented at the 2026 SNO Annual Meeting reinforce the drug's durability: confirmed objective response rates reached 46.6% in adults and 55.4% in children, with deep responses (>50% tumor volume reduction) seen in 70.4% and 64.5% of responders, respectively. Crucially, new-onset side effects became less frequent with each passing year of treatment.
Key Takeaways
Why it matters: NF1-associated plexiform neurofibromas are notoriously difficult to treat, and options after MEK inhibitor failure have been limited. These findings suggest that MEK inhibitor sequencing is a viable strategy, opening a new clinical pathway for patients who've exhausted their first-line option.